Tata Digital has hired CureFit’s chief executive as part of a $75m investment for the UC-RNT Fund-backed health and fitness app developer.

IP Group sold a $5m stake to incoming shareholder Celltrion as part of a series A round for Iksuda, a spinout of Bath originally called Glythera.

The low Earth orbit mapping technology provider has raised more than $100m altogether, having picked up series A financing from Weru Investment in 2018.

Stablix Therapeutics has launched with $63m in equity financing to commercialise research pioneered in Henry Colecraft’s laboratory at Columbia University.

IP Group has participated in a $92m series C round for Pulmocide, a developer of treatments for respiratory diseases that was spun out of Imperial College London.

Respective endowments for University of Macau and Macau University of Science and Technology have contributed to a series A round.

Undisclosed investors have supplied series D funding for the Tsinghua-backed bookkeeping and taxation software developer.

The UC Berkeley spinout-derived genetic eye disease therapeutics company has launched with fresh funding featuring new and founding investors.

UPenn, Penn Medicine and OUP all contributed to an oversubscribed series A round for UPenn spinout Interius Biotherapeutics.

Based on research at Stanford, Bluestar Genomics is working on a non-invasive test for pancreatic cancer.